Loading...
•
Mar 31, 2024
Amneal Q1 2024 Earnings Report
Amneal reported record levels of revenues and double-digit top-line growth across all three segments.
Key Takeaways
Amneal Pharmaceuticals, Inc. announced strong first quarter 2024 results, with net revenue of $659 million, an 18% increase compared to the first quarter of 2023. All three segments experienced double-digit top-line growth. The company reached a settlement in principle on a nationwide opioids settlement and affirmed its 2024 full year guidance.
Net revenue for Q1 2024 reached $659 million, an 18% increase year-over-year.
GAAP net loss was $92 million, including a $94 million pre-tax charge for an opioids settlement.
Adjusted EBITDA increased by 31% to $152 million.
Adjusted diluted EPS was $0.14, compared to $0.12 in the first quarter of 2023.
Revenue by Segment
Forward Guidance
The Company is affirming its previously provided full year 2024 guidance.
Positive Outlook
- Net revenue: $2.55 billion - $2.65 billion
- Adjusted EBITDA: $580 million - $620 million
- Adjusted diluted EPS: $0.53 - $0.63
- Operating cash flow: $260 million - $300 million
- Capital expenditures: $60 million - $70 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...